儿童与年轻成人急性淋巴细胞白血病的种族和民族差异:八项儿童肿瘤学组队列研究的二次分析
该二次分析纳入八项儿童肿瘤学组试验中2004年1月1日至2019年12月31日入组的24979例0-30岁新诊断急性淋巴细胞白血病患者,其中21152例有种族或民族数据。非西班牙裔白人5年无事件生存率为87.4%,西班牙裔为82.8%(HR 1.37),非西班牙裔黑人为81.8%(HR 1.45)。调整疾病预后因素和保险状态后,西班牙裔患者的HR降至1.11,非西班牙裔黑人患者的HR降至1.32。差异仅限于B细胞急性淋巴细胞白血病,T细胞组未见差异。
要点
- 非西班牙裔白人5年无事件生存率87.4%,西班牙裔82.8%(HR 1.37),非西班牙裔黑人81.8%(HR 1.45)。
- 调整疾病预后因素和保险状态后,西班牙裔HR从1.37降至1.11,非西班牙裔黑人HR从1.45降至1.32。
- 无事件生存和总生存差异仅限于B细胞急性淋巴细胞白血病,T细胞组未见差异。
核心结论
- B细胞急性淋巴细胞白血病患者的结局存在显著的种族和民族差异,而T细胞急性淋巴细胞白血病患者中未观察到这些差异。
- 未来需要对复发患者、医疗可及性和质量以及其他潜在的结构性种族主义方面进行研究,以指导旨在消除种族和民族差异的干预措施。
研究设计与样本
- 二次分析纳入了八项已完成的儿童肿瘤学组试验(NCT00103285、NCT00075725、NCT00408005、NCT01190930、NCT02883049、NCT02112916、NCT02828358和NCT00557193)。
- 研究对象为2004年1月1日至2019年12月31日期间在美国、加拿大、澳大利亚和新西兰的住院和门诊中心入组的0-30岁新诊断急性淋巴细胞白血病患者,且有种族或民族数据。
- 共24979例合格患者入组,其中21152例有种族或民族数据;11849例(56.0%)为男性,9303例(44.0%)为女性。
- 种族和民族分类为非西班牙裔白人、西班牙裔、非西班牙裔黑人、非西班牙裔亚裔和非西班牙裔其他。
- 通过多变量回归模型分析临床和生物学疾病预后因素及保险状态的相对贡献,分别在全队列和B细胞谱系与T细胞谱系疾病患者中进行。
主要发现
- 非西班牙裔白人患者5年无事件生存率为87.4%(95% CI 86.7-88.0%),西班牙裔患者为82.8%(81.4-84.1%;HR 1.37,95% CI 1.26-1.49;p<0.0001),非西班牙裔黑人患者为81.8%(79.3-84.0;HR 1.45,1.28-1.65;p<0.0001)。
- 非西班牙裔亚裔患者5年无事件生存率为88.1%(95% CI 85.5-90.3%),非西班牙裔其他患者为82.8%(76.4-87.6%)。
- 西班牙裔患者中无事件生存率较低的情况被疾病预后因素和保险状态大幅减弱(HR从1.37 [1.26-1.49;p<0.0001] 降至1.11 [1.00-1.22;p=0.045])。
- 非西班牙裔黑人患者风险增加仅轻微减弱(HR从1.45 [1.28-1.65;p<0.0001] 降至1.32 [1.14-1.52;p<0.0001])。
- 5年总生存率:非西班牙裔亚裔患者93.6%(91.5-95.1%),非西班牙裔白人患者93.3%(92.8-93.7%),西班牙裔患者89.9%(88.7-90.9%),非西班牙裔黑人患者89.7%(87.6-91.4%),非西班牙裔其他患者88.9%(83.2-92.7%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来需要对复发患者、医疗可及性和质量以及其他潜在的结构性种族主义方面进行研究,以指导旨在消除种族和民族差异的干预措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have identified racial and ethnic disparities in childhood acute lymphocytic leukaemia survival. We aimed to establish whether disparities persist in contemporaneous cohorts and, if present, are attributable to differences in leukaemia biology or insurance status. METHODS: Patients with newly diagnosed acute lymphocytic leukaemia in inpatient and outpatient centres in the USA, Canada, Australia, and New Zealand, aged 0-30 years, who had race or ethnicity data available, enrolled on eight completed Children's Oncology Group trials (NCT00103285, NCT00075725, NCT00408005, NCT01190930, NCT02883049, NCT02112916, NCT02828358, and NCT00557193) were included in this secondary analysis. Race and ethnicity were categorised as non-Hispanic White, Hispanic, non-Hispanic Black, non-Hispanic Asian, and non-Hispanic other. Event-free survival and overall survival were compared across race and ethnicity groups. The relative contribution of clinical and biological disease prognosticators and insurance status was examined through multivariable regression models, both among the entire cohort and among those with B-cell lineage versus T-cell lineage disease. FINDINGS: Between Jan 1, 2004, and Dec 31, 2019, 24 979 eligible children, adolescents, and young adults with acute lymphocytic leukaemia were enrolled, of which 21 152 had race or ethnicity data available. 11 849 (56·0%) were male and 9303 (44·0%) were female. Non-Hispanic White patients comprised the largest racial or ethnic group (13 872 [65·6%]), followed by Hispanic patients (4354 [20·6%]), non-Hispanic Black patients (1517 [7·2%]), non-Hispanic Asian (n=1071 [5·1%]), and non-Hispanic other (n=338 [1·6%]). 5-year event-free survival was 87·4% (95% CI 86·7-88·0%) among non-Hispanic White patients compared with 82·8% (81·4-84·1%; hazard ratio [HR] 1·37, 95% CI 1·26-1·49; p<0·0001) among Hispanic patients and 81·8% (79·3-84·0; HR 1·45, 1·28-1·65; p<0·0001) among non-Hispanic Black patients. Non-hispanic Asian patients had a 5-year event-free survival of 88·1% (95% CI 85·5-90·3%) and non-Hispanic other patients had a survival of 82·8% (76·4-87·6%). Inferior event-free survival among Hispanic patients was substantially attenuated by disease prognosticators and insurance status (HR decreased from 1·37 [1·26-1·49; p<0·0001] to 1·11 [1·00-1·22; p=0·045]). The increased risk among non-Hispanic Black patients was minimally attenuated (HR 1·45 [1·28-1·65; p<0·0001] to 1·32 [1·14-1·52; p<0·0001]). 5-year overall survival was 93·6% (91·5-95·1%) in non-Hispanic Asian patients, 93·3% (92·8-93·7%) in non-Hispanic White patients, 89·9% (88·7-90·9%) in Hispanic, 89·7% (87·6-91·4%) in non-Hispanic Black patients, 88·9% (83·2-92·7%) in non-Hispanic other patients. Disparities in overall survival were wider than event-free survival (eg, among non-Hispanic other patients, the HR for event-free survival was 1·43 [1·10-1·85] compared with 1·74 [1·27-2·40] for overall survival). Disparities were restricted to patients with B-cell acute lymphocytic leukaemia, no differences in event-free survival or overall survival were seen in the T-cell acute lymphocytic leukaemia group. INTERPRETATION: Substantial disparities in outcome for B-cell acute lymphocytic leukaemia persist by race and ethnicity, but are not observed in T-cell acute lymphocytic leukaemia. Future studies of relapsed patients, access to and quality of care, and other potential aspects of structural racism are warranted to inform interventions aimed at dismantling racial and ethnic disparities. FUNDING: National Cancer Institute and St Baldrick's Foundation.
引用
- Gupta S, Dai Y, Chen Z, et al. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. Lancet Haematol. 2023. PMID: 36725118. doi:10.1016/S2352-3026(22)00371-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。